Patients receiving hematological treatments vs controls
| Medication . | COVID outcome . | Patients affected, N . | Controls affected, N . |
|---|---|---|---|
| Erythropoietin (n = 460) | Infection | 10 | 1 |
| Symptomatic | 5 | 1 | |
| Hospitalized | 3 | 0 | |
| Severe | 2 | 0 | |
| Death | 1 | 0 | |
| Rituximab (n = 275) | Infection | 8 | 1 |
| Symptomatic | 6 | 0 | |
| Hospitalized | 5 | 0 | |
| Severe | 4 | 0 | |
| Death | 1 | 0 |
| Medication . | COVID outcome . | Patients affected, N . | Controls affected, N . |
|---|---|---|---|
| Erythropoietin (n = 460) | Infection | 10 | 1 |
| Symptomatic | 5 | 1 | |
| Hospitalized | 3 | 0 | |
| Severe | 2 | 0 | |
| Death | 1 | 0 | |
| Rituximab (n = 275) | Infection | 8 | 1 |
| Symptomatic | 6 | 0 | |
| Hospitalized | 5 | 0 | |
| Severe | 4 | 0 | |
| Death | 1 | 0 |
Controls were nonhematological. Most of them did not receive erythropoietin or rituximab.